In rare cases, during concomitant ingestion of certain antibiotics (such as penicillin and tetracycline groups) there was a decrease in estradiol levels.

Substances largely exposed conjugation (such as acetaminophen) may increase the bioavailability of estradiol due to competitive inhibition of conjugation in the process of absorption.

As a result of the effect of equipoise on glucose tolerance in some cases may change the need for oral antidiabetics or insulin.


  • Interaction with alcohol


Excessive alcohol consumption  may lead to an increase in circulating levels of estradiol.

Cyclo-Proginova is not applicable for the purpose of contraception.

If necessary contraception must be used non-hormonal methods (except the calendar and temperature methods). If you suspect a pregnancy should stop taking the pills for as long as the pregnancy will not be excluded .

In the presence or worsening of any of the following conditions or risk factors before you begin or continue equipoise should weigh the individual risks and benefits of treatment.


  • Venous thromboembolism


A number of randomized controlled and tkazhe epidemiological studies found an increased relative risk of developing venous thromboembolism , ie deep vein thrombosis or pulmonary embolism.Therefore, the appointment  for women with risk factors  of treatment should be carefully weighed and discussed with the patient.

Risk factors for include a personal and family history ( in the presence of the next of kin in a relatively early age may indicate genetic disposition) and severe obesity. The risk of equipoise also increases with age. The question of the possible role of varicose veins in the development of  remains controversial.

The risk of  may be temporarily increased with prolonged immobilization, “large” and the planned operations or massive trauma injury. Depending on the cause or duration of immobilization should decide whether a temporary cessation.

It should immediately discontinue treatment if symptoms of thrombotic disorders or suspected their appearance.


  • Arterial thromboembolism


In randomized controlled trials with long-term use of combined conjugated estrogens and medroxyprogesterone acetate was no evidence of a positive effect on the cardiovascular system. In large-scale clinical trials of this compound was found possible increase in the risk of coronary heart disease in the first year of application. Also, the increased risk of stroke was found. So far, with other drugs for equipoise has not been long-term randomized controlled trials to identify a positive effect on the morbidity and mortality related to the cardiovascular system. Therefore unknown whether the increased risk , containing other types of estrogens and progestogens.


  • endometrial cancer


Prolonged estrogen alone increases the risk of endometrial hyperplasia or carcinoma. Studies have confirmed that the addition of progestogen reduces the risk of endometrial hyperplasia and cancer.


  • Mammary cancer


According to the results of clinical trials and observational studies have found an increase in the relative risk of developing breast cancer in women who use  for several years. This may be due to an earlier diagnosis, biological effects of equipoise, or a combination of both factors. The relative risk increases with duration of treatment and possible further increases in estrogen combined with progestogen. This increase is comparable to the increase in delaying the onset of natural menopause, the risk of breast cancer in women each year, as well as obesity and alcohol abuse. The increased risk gradually decreases to normal levels during the first few years after stopping